Our research indicates that the erythropoietin resistance index (ERI) is not only a biomarker for the treatment response of anemia in maintenance hemodialysis (MHD) patients but also a predictor of stroke and all-cause mortality risk. Here, EPO is linked to anemia (phenotype).